News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MediGene AG (MDGEF.PK) Announces Market Launch Of Veregen®: In Belgium, Denmark And Finland


6/12/2014 7:55:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Martinsried/Munich, 12 June 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces market launches of Veregen® in further three European markets. Medigene's marketing partner Will-Pharma has launched the drug for the treatment of genital warts in Belgium and the marketing partner Azanta A/S will start the launch of Veregen® in Denmark and Finland within the next few weeks.

Veregen® is already available in the USA, in 12 European countries (Germany, Austria, Switzerland, Spain, the Netherlands, Norway, Sweden, the Czech Republic, Poland, Serbia, Hungary, Slovakia) and Taiwan. Market approvals for Veregen® have been granted in a number of other countries. Further market launches and approvals of Veregen® are expected in 2014. Several marketing agreements have been concluded in Europe, Asia, and America.

About Veregen®: Veregen®, a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. In its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment (Veregen®) has been included in the current European guideline on the treatment of genital warts, the 2012 European Guideline for the Management of Anogenital Warts.

About Will-Pharma: Will-Pharma markets and promotes its own ethical products, food supplements and medical devices through its well trained sales force. With its head offices in the three countries of Benelux, Will-Pharma has more than 90 years of experience in the development and sale of drugs, medical devices, and food supplements. Moreover, Will-Pharma has a long standing distribution agreement with Daiichi-Sankyo. More information on Will-Pharma: www.willpharma.com.

About Azanta: Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women's and men's health, and addiction medicine. The vision of Azanta A/S is to become an international market leader for specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets nine specialty pharma products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. In addition, Azanta A/S has a portfolio of low-risk development projects for commercialization in the near term. For further information, please visit www.azanta.com.

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partners. Medigene has various drug candidates in clinical development and it is developing highly innovative treatment platforms. For more information, please visit www.medigene.com .

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene®, Veregen®, EndoTAG® and RhuDex® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact
Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES